Neoadjuvant cemiplimab for stage II to IV cutaneous squamous cell carcinoma
Giving four doses of cemiplimab before surgery for resectable cutaneous squamous cell carcinoma eliminated all viable tumour in half of patients and left only minimal residual disease in another 13 percent, opening the way to smaller operations and less radiotherapy.
Overview
Phase 2 study of 79 patients with resectable stage II to IV (M0) cutaneous squamous cell carcinoma treated with up to four doses of neoadjuvant cemiplimab followed by surgery.
Pathological complete response was 50.6 percent and major pathological response (10 percent or less viable tumour) a further 12.7 percent; radiological response underestimated pathological response, and adverse events were consistent with PD-1 blockade.
- Pathological complete response 50.6 percent; major pathological response 12.7 percent.
- Objective radiological response 68.4 percent.
Neoadjuvant cemiplimab is now used to shrink large or function-threatening cutaneous squamous cell carcinomas before surgery, and pathological response is being studied as a guide to omitting adjuvant radiotherapy.
- Single-arm; long-term recurrence-free survival data are maturing.
- Surgical de-escalation after complete response is not yet standard.
Similar pages
not linked directly; found by shared links- Key paperC-POST: adjuvant cemiplimab versus placebo in high-risk cutaneous squamous cell carcinoma
Shares Advanced cutaneous squamous cell carcinoma, Cemiplimab, New England Journal of Medicine.
- Key paperPD-1 blockade with cemiplimab in advanced cutaneous squamous cell carcinoma (EMPOWER-CSCC-1)
Shares Advanced cutaneous squamous cell carcinoma, Cemiplimab, New England Journal of Medicine.
- TrialStudy of Intralesional Cemiplimab in Adult Patients With Early Stage Cutaneous Squamous Cell Carcinoma
Shares Advanced cutaneous squamous cell carcinoma, Cemiplimab.
- TrialStudy Evaluating Cemiplimab Alone and Combined With RP1 in Treating Advanced Squamous Skin Cancer
Shares Advanced cutaneous squamous cell carcinoma, Cemiplimab.
- TrialAn Open-label Study Using ASP-1929 Photoimmunotherapy in Combination With Anti-PD1 Therapy in EGFR Expressing Advanced Solid Tumors
Shares Advanced cutaneous squamous cell carcinoma, Cemiplimab.
- Key paperEMPOWER-Cervical 1: cemiplimab versus chemotherapy in recurrent cervical cancer after platinum
- TrialEMPOWER-CSCC-1
Shares Advanced cutaneous squamous cell carcinoma, Cemiplimab.